Characterization of isoniazid incorporation into chitosan-poly(aspartic acid) nanoparticles
Source abstract
Abstract
The incorporation of the drug Isoniazid (an anti-tuberculosis drug) into nanoparticles of polyelectrolyte chitosan-poly(aspartic acid) complexes was carried out by the ionotropic gelation technique, adding a sodium polyaspartate solution containing the drug to a chitosan solution in different proportions in a mass ratio (mg/mg) Isoniazid/Chitosan. This was confirmed by MALDI-TOF/MS, ESI/MS, FTIR, and UV-Vis. The lowest average particle diameter (PD), estimated by DSL, was 148.5 ± 1 nm corresponding to an Isoniazid/chitosan ratio (mg/mg) of 0.5:1. FE-SEM showed nanoparticles in the order of 100–300 nm; whereas AFM showed semi-spherical particle morphology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Surfactants and Colloidal Systems · Polymer Surface Interaction Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Departamento de Química Orgánica, Universidad Nacional Mayor de San Marcos, Lima, Peru
Biomedical Engineering, The University of Memphis, Memphis, Tennessee, USA
Department of Chemistry, University of Wyoming, Laramie, Wyoming, USA
Centro Nacional de Alta Tecnología “Dr. Franklin Chang Díaz”, Laboratorio Nacional de Nanotecnología (LANOTEC), San José, Costa Rica
POLIUNA, Escuela de Química, Universidad Nacional, Heredia, Costa Rica
Department of Engineering and Materials Chemistry, Centro de Investigación en Materiales Avanzados, Complejo Industrial Chihuahua, Chihuahua, Mexico
References (48)
Show source-provided references
1. 10.3109/02652048.2011.59943710.3109/02652048.2011.599437 ↗
2. 10.1056/nejmra120089410.1056/nejmra1200894 ↗
3. 10.1016/j.ijregi.2022.01.00410.1016/j.ijregi.2022.01.004 ↗
4. 10.18433/j3m59p10.18433/j3m59p ↗
5. 10.1016/j.imu.2022.10084910.1016/j.imu.2022.100849 ↗
6. 10.1183/09031936.0007730710.1183/09031936.00077307 ↗
7. 10.2174/13895570778233174010.2174/138955707782331740 ↗
8. 10.1016/j.ijid.2021.03.09310.1016/j.ijid.2021.03.093 ↗
9. 10.3109/21691401.2015.100850810.3109/21691401.2015.1008508 ↗
10. 10.4103/0253-7613.7188710.4103/0253-7613.71887 ↗
11. 10.2174/221173850666618062512003810.2174/2211738506666180625120038 ↗
12. 10.1002/1521-4184(200106)334:6<189::AID-ARDP189>3.0.CO;2-610.1002/1521-4184(200106)334:6<189::AID-ARDP189>3.0.CO;2-6 ↗
13. 10.4314/tjpr.v6i4.1466510.4314/tjpr.v6i4.14665 ↗
14. 10.1016/j.tube.2003.07.00110.1016/j.tube.2003.07.001 ↗
15. 10.1093/jac/dkl12810.1093/jac/dkl128 ↗
16. Pandey, R.; Sharma, S.; Khuller, G. K. Oral Poly(Lactide-co-Glycolide) Nanoparticle Based Antituberculosis Drug Delivery: Toxicological and Chemotherapeutic Implications. Indian J. Exp. Biol. 2006, 44, 459–467.
17. 10.1093/jac/dkh41110.1093/jac/dkh411 ↗
18. 10.1016/j.colsurfb.2012.12.00810.1016/j.colsurfb.2012.12.008 ↗
19. 10.1021/acsabm.9b0000310.1021/acsabm.9b00003 ↗
20. 10.1016/j.eurpolymj.2013.06.02010.1016/j.eurpolymj.2013.06.020 ↗
21. 10.1016/j.ijbiomac.2020.10.19210.1016/j.ijbiomac.2020.10.192 ↗
22. 10.1080/00914037.2022.202944010.1080/00914037.2022.2029440 ↗
23. 10.1021/ja990276a10.1021/ja990276a ↗
24. 10.1002/hlca.20170016610.1002/hlca.201700166 ↗
25. 10.1021/ol010036b10.1021/ol010036b ↗
26. 10.1016/j.progpolymsci.2005.12.00110.1016/j.progpolymsci.2005.12.001 ↗
27. 10.1016/j.ijpharm.2008.04.04210.1016/j.ijpharm.2008.04.042 ↗
28. 10.3390/polym1112201010.3390/polym11122010 ↗
29. 10.1021/ac035331j10.1021/ac035331j ↗
30. 10.1002/rcm.321910.1002/rcm.3219 ↗
31. 10.1042/bj126044910.1042/bj1260449 ↗
32. 10.1016/S1472-9792(08)70011-810.1016/S1472-9792(08)70011-8 ↗
33. 10.1007/s00396-007-1785-710.1007/s00396-007-1785-7 ↗
34. 10.1007/s13361-011-0150-810.1007/s13361-011-0150-8 ↗
35. 10.1016/S1044-0305(01)00230-610.1016/S1044-0305(01)00230-6 ↗
36. 10.2298/JSC110201145D10.2298/JSC110201145D ↗
37. 10.1590/0074-0276014045810.1590/0074-02760140458 ↗
38. 10.5897/AJPP2014.419710.5897/AJPP2014.4197 ↗
39. 10.1080/10242422.2017.129523110.1080/10242422.2017.1295231 ↗
40. 10.1016/j.ijbiomac.2018.09.19410.1016/j.ijbiomac.2018.09.194 ↗
41. 10.1016/j.polymertesting.2011.02.00710.1016/j.polymertesting.2011.02.007 ↗
42. Hebda E.; Pielichowski J. A. N. Poly (Aspartic Acid) – Based Catalysts for the Oxidation Reactions Zastosowanie Katalizatorów Na Bazie Poli (Kwasu Asparaginowego) W Reakcjach Utleniania. Czas Tech Chem 2008.
43. 10.1021/jp903791410.1021/jp9037914 ↗
44. 10.1016/j.jsps.2020.10.00810.1016/j.jsps.2020.10.008 ↗
45. 10.1016/j.eurpolymj.2021.11076710.1016/j.eurpolymj.2021.110767 ↗
46. 10.3390/pharmaceutics1212119610.3390/pharmaceutics12121196 ↗
47. 10.1016/B978-0-323-46143-6.00022-110.1016/B978-0-323-46143-6.00022-1 ↗
48. 10.1515/epoly-2021-008510.1515/epoly-2021-0085 ↗